


 Cite this: *RSC Adv.*, 2025, 15, 24650

# Design, synthesis and anticancer evaluation of novel hydrazide-2-oxindole analogues as GSK-3 $\beta$ kinase inhibitors†

 Ashok Madarakhandi,<sup>ab</sup> Sujeet Kumar,<sup>c</sup> Nishith Teraiya,<sup>d</sup> Dominique Schols,<sup>e</sup> Soujanya J. Vastrad,<sup>f</sup> P. Shyamjith,<sup>g</sup> Bibha Choudhary,<sup>g</sup> Arzoo Rai<sup>h</sup> and Subhas S. Karki<sup>\*,ab</sup>

GSK-3 $\beta$  plays an essential role in cancer progression, making it a promising target for therapeutic intervention with glycogen synthase kinase (GSK-3 $\beta$ ) inhibitors. The designed compounds were discovered for their potential role against the proliferation of cancer *via* targeting GSK-3 $\beta$ . In the present study, hydrazide-2-oxindole analogues were designed, synthesised, and evaluated for anticancer efficacy against GSK-3 $\beta$ . Compounds were screened against Capan-1, HCT-116, LN-229, MCI-4460, DND-41, HL-60, K-562, MOLT4, Z-138 cells and normal cell line HEK 293. Among the compounds, **6Eb** and **6Ec** showed the highest selective cytotoxicity against prostate cancer (Capan-1) with CC<sub>50</sub> values of 9.40  $\mu$ M, and 8.25  $\mu$ M, respectively. Furthermore, the mechanism of the anticancer effect was evidenced by **6Eb** and **6Ec** against GSK-3 $\beta$  kinase with IC<sub>50s</sub> of 11.02  $\mu$ M and 59.81  $\mu$ M, respectively. In addition, elevation of  $\beta$ -catenin and downregulation of NF- $\kappa$ B and STAT3 in the western blot by **6Eb** evidenced inhibition of GSK-3 $\beta$  kinase as the cause of cytotoxicity. Furthermore, *in vitro* results were supported by docking scores of  $-10.5$  kcal mol<sup>-1</sup> and  $-8.8$  kcal mol<sup>-1</sup>, respectively, as compared to **bio-acetoxime** ( $-7.7$  kcal mol<sup>-1</sup>). Furthermore, the higher stability in molecular dynamics simulations validated the docking approach and indicated anti-cancer effects by inhibiting GSK-3 $\beta$ . In addition, the density functional theory analysis identified electronic distribution in compounds, which was correlated to the findings of docking and molecular dynamic simulation on their participation in polar and lipophilic interactions with kinase. Moreover, the compounds meet the drug-likeness criteria, suggesting they could be candidates for the development of drugs against cancer that target GSK-3 $\beta$ .

 Received 13th February 2025  
 Accepted 5th July 2025

DOI: 10.1039/d5ra01063b

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

<sup>a</sup>Department of Pharmaceutical Chemistry, Dr Prabhakar B. Kore Basic Science Research Center, Off-Campus, KLE College of Pharmacy, Bengaluru-560010, India. E-mail: [subhasskarki@gmail.com](mailto:subhasskarki@gmail.com); [subhashkarki@klepharmblr.org](mailto:subhashkarki@klepharmblr.org); Fax: +91 8023425373; Tel: +91 80 23325611

<sup>b</sup>KLE Academy of Higher Education & Research, Belagavi-590010, Karnataka, India

<sup>c</sup>Department of Pharmaceutical Chemistry, Nitte College of Pharmaceutical Sciences (Nitte-Deemed to be University, Mangaluru), Yelahanka, Bengaluru, Karnataka 560064, India

<sup>d</sup>Department of Pharmaceutical Chemistry, K. B. Institute of Pharmaceutical Education and Research, Kadi Sarva Vishvavidyalaya, Gandhinagar 382023, Gujarat, India

<sup>e</sup>Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, KU Leuven, B-3000 Leuven, Belgium

<sup>f</sup>Department of Pharmacy Practice, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bengaluru 560054, Karnataka, India

<sup>g</sup>Institute of Bioinformatics and Biotechnology, Electronic City Phase 1, Bengaluru, India

<sup>h</sup>School of Applied Material Science, Central University of Gujarat, Gandhinagar 382030, Gujarat, India

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d5ra01063b>

## 1. Introduction

Many human disorders, including cancer, have been linked to abnormal GSK-3 $\beta$  activity, which suggests that it could be a therapeutic target for anticancer treatment. In around 25 distinct cancer types, GSK-3 $\beta$  has been recognized as a possible therapeutic target in recent investigations, with many of these studies being published in the last decade. In addition, there is growing evidence that blocking GSK-3 $\beta$  activity shields healthy cells and tissues from the negative consequences linked to traditional cancer treatments.<sup>1-4</sup> Although only active GSK-3 $\beta$  is expressed in cancer cells, abnormal nuclear accumulation of GSK-3 $\beta$  has been recognized as a characteristic of cancer cells in malignant tumors of various origins.<sup>5-8</sup> Recent findings have highlighted the critical involvement of GSK-3 $\beta$  in the anticancer immune response.<sup>9-13</sup>

GSK-3, a serine/threonine kinase, exists in two isoforms: GSK-3 $\alpha$  and GSK-3 $\beta$ . Multiple processes, such as phosphorylation, protein complex formation, and subcellular distribution, contribute to GSK-3, activity regulation.<sup>14,15</sup> So far, GSK-3 $\beta$  has been linked to several illnesses, including diabetes, cancer,



bipolar disorder, and neurodegenerative disorders. GSK-3 $\beta$  regulates apoptosis, proliferation, and the cell cycle.<sup>16</sup> In contrast; GSK-3 $\beta$  has been described as a tumour suppressor in malignancies such as skin, breast, oral cavity, and lung cancer. There are two types of GSK-3 $\beta$  inhibitors: non-ATP competitive inhibitors and ATP competitive inhibitors. Non-ATP competitive inhibitors form a weak binding association with the enzyme and do not compete with ATP concentration, providing a distinct pharmacological advantage. The bulk of known GSK-3 $\beta$  inhibitors are ATP-competitive, targeting the ATP-binding region of GSK-3 $\beta$ . As illustrated in Fig. 1, there are multiple inhibitors from various chemical classes, including bisindolylmaleimide, indolyl-maleimide, pyrimidine, maleimide, indirubine, paullone, pyrazolamide, oxadiazole, thiazole, and thiadiazole.<sup>17,18</sup>

Staurosporine, a natural substance from *Streptomyces staurosporeus*, inhibits GSK-3 $\beta$  with an IC<sub>50</sub> of 15 nM.<sup>19</sup> Compound A is a 7-azaindazolyl-indolyl-maleimide analogue with a morpholine side chain that fills the expanded pocket *via* H-bonds with Lys183 and Asp200.<sup>19</sup> The ketone and amine of indolyl-maleimide inhibitor, B, interacted *via* polar contacts (Fig. 1). Furthermore, the side chain of aliphatic amino alcohol stabilized the complex from the end *via* an H-bond with Gln185.<sup>20</sup> The nitrogen in the pyrimidine and anilino rings of compound C was connected to Tyr134 and Val135 *via* H-bonds. While in the kinase's back pocket, amide and hydroxyl groups protruded and

established additional hydrogen bond with Asp200. Furthermore, their oral bioavailability was comparable in rats ( $F = 65\%$ ;  $t_{1/2} = 3$  h) and mice ( $F = 67\%$ ;  $t_{1/2} = 4.4$  h).<sup>21</sup> In *in vivo* research on zebrafish embryos, maleimide analogue D demonstrated a higher affinity and IC<sub>50</sub> of 92  $\mu$ M. An SAR investigation found that substituents at the C-4 or C-5 locations fit into the front area of the ATP site. Larger substitutions had more hydrophobic interactions and a stronger binding affinity.<sup>22</sup> Likewise, indirubin analogue E showed higher selectivity against GSK-3 $\beta$  with an IC<sub>50</sub> of 22 nM compared to other kinases. The isatin ring's amino and ketone groups created strong hydrogen bonds and lipophilic contacts to stabilize the complex.<sup>23,24</sup> Paullone analogue F, containing a cyclic amide and a nitro group that enhanced molecular interactions with the target, demonstrated potent kinase inhibition with an IC<sub>50</sub> of 4 nM.<sup>25</sup> Likewise, pyrazolamide analogue G exhibited strong kinase binding through a combination of polar and nonpolar interactions, mediated by its amide linkage and phenyl ring, also resulting in an IC<sub>50</sub> of 4 nM.<sup>26</sup> The compound 'H' interacts with the ATP binding site, where the O1 oxygen atom and hydrogen atom on the C2-carbon of the benzodioxole form hydrogen bonds with the amide NH hydrogen and the carbonyl oxygen of Val135 located in the hinge region, respectively. The 4-methoxy-3-fluorobenzyl group occupies the hydrophobic pocket, while both the N3 and N4 nitrogen atoms of the oxadiazole are involved in a distinctive hydrogen bond network connecting Lys85–Glu97–Asp200




Fig. 1 Pharmacophores of GSK-3 $\beta$  inhibitors. The key structural components involved in the interaction are highlighted.



through two water molecules.<sup>27</sup> Moreover, the urea linkage of compound **I** formed a key interaction with Gln137 at the centre of the binding site. The methoxyphenyl ring further stabilized the complex by occupying the rear pocket and forming close contact with Ile62, Lys183, and Gln185.<sup>28</sup> Additionally, the thiadiazolidinone ring ketones in **TDZD-8 (J)** established hydrogen connections with Lys206 and Arg96.<sup>29</sup> Pharmacophore searches revealed common pharmacophoric components such as amide and urea linkages (open and cyclic), oxime, and a fused ring involved in polar contact. In addition, the core ATP binding site was occupied by the parent heterocyclic ring, which included pyrrole, pyrazole, oxadiazole, thiazole, thiazolidine, indole, and pyrimidines (Fig. 1). Furthermore, substituent's like nitro, methoxy, bromo, fluoro, methyl, and ethyl boosted activity by interacting with the backside of the pocket. Inspired by these findings, we decided to include heteryl rings, such as triazole and indole rings, as well as the linkage of hydrazide in our new molecules to preserve similar types of interactions.

### 1.1. Rationale and design

Several indolymaleimides, such as **A** and **B**, have been developed to be effective GSK-3 $\beta$  inhibitors based on staurosporine, a microbial alkaloid discovered as an initial GSK-3 $\beta$  inhibitor (Fig. 1). The majority of these indolymaleimides exhibit toxicity, low solubility, and poor selectivity, making them inappropriate for treating disorders such as diabetes, Alzheimer's disease, and cancer.<sup>19,30</sup> As a result, we chose smaller thiadiazolidinone synthetic analogues **TDZD-8** and **10**, the first non-competitive GSK-3 $\beta$  inhibitors that lack all of the

aforementioned toxicities and exhibit drug-like characteristics. **TDZD-8** and **10** inhibited GSK-3 $\beta$  at 2 and 10  $\mu$ M, respectively. They trigger apoptosis, causing extremely rapid cell death and loss of membrane integrity.<sup>29</sup> Furthermore, indirubin-3-monoxime analogues such as **bio-acetoxime**, and **44** were more selective against GSK-3 $\beta$  than other kinases, with affinities of 22 nM and 3 nM, respectively.<sup>31</sup> In SY5Y-MYCN cells, **bio-acetoxime** significantly lowers c-MYC expression and p-SMAD3 levels. It also reduces the viability of KCN, KCN, SY5Y, Kelly, and IMR32 cells by inducing apoptosis.<sup>32</sup> The increased potency of these analogues prompted us to investigate them as potential leads for the development of design compounds *via* molecular hybridization approach. The thiadiazolidinone ring's ketones in **TDZD-8** formed two hydrogen connections with Lys206 and Arg96. To keep the binding pattern consistent, we bioisosterically substituted the thiadiazolidinones with a triazole ring in our proposed molecule. Furthermore, the amino and ketone groups of the indole ring in **bio-acetoxime** and compound **44** formed strong H-bonds with Asp133, Val135, and Asp200. Additionally, the indole ring increased binding affinity through numerous lipophilic interactions with Ala83, Tyr134, and Leu188. Because of its significant contribution, we bioisosterically replaced the benzyl ring of **TDZD-8** in our developed compound with indole moiety to retain a similar interaction. Furthermore, the monoxime group in the **bio-acetoxime** stabilized protein-ligand complex by filling the back side of the pocket. To preserve the same stability and binding connection in our developed compounds, we added different substituted hydrazides to the indole ring (Fig. 2).




Fig. 2 Modification strategies of designed compounds.



In the present study, a series of indole-linked triazoles (**6Ab–Ed**) were designed, synthesized, and evaluated for their anti-proliferative activity. Their mechanism of action was elucidated through a combination of GSK-3 $\beta$  kinase inhibition assays, western blot analysis, and *in silico* studies.

## 2. Materials and methods

### 2.1. Chemistry


All chemicals and reagents were procured from BLD Pharmatech, Hyderabad, and Spectrochem Bengaluru, India. The progress of reactions was monitored by thin layer chromatography (TLC) on pre-coated silica gel 60 F254 plates (Merck, Germany) with chloroform and ethanol as the mobile phase. Melting points (MP) were determined using a digital melting point apparatus (DBK 50 Hz, 220 V) and reported uncorrected. Proton and carbon nuclear magnetic resonance ( $^1\text{H}/^{13}\text{C}$  NMR) spectra were recorded on a 400/100 MHz Bruker instrument in  $\text{CDCl}_3/\text{DMSO}-d_6$  and chemical shift values ( $J$ ) were reported in hertz (Hz). Fourier-transform infrared (FT-IR) spectra were obtained on JASCO460+ FTIR spectrophotometer. High-resolution mass spectrometry (HRMS) data were collected by electrospray ionization (ESI) technique using Waters Synapt G2 QTOF mass spectrometry. The 1-(prop-2-yn-1-yl)indoline-2,3-dione (**3**) was synthesized by reacting indole-2,3-dione (**1**) with 3-bromoprop-1-yne (**2**) in presence of  $\text{K}_2\text{CO}_3$  in dimethylformamide (DMF).<sup>33</sup>

The respective aryl azides (**4A–E**) were obtained by reacting aryl bromides with sodium azide as per literature.<sup>33</sup> Other intermediate derivatives (**5A–D**) were prepared according to literature (Scheme 1).<sup>34</sup>

**2.1.1. Synthesis of 1-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)indoline-2,3-dione (5E).** 1-(Prop-2-yn-1-yl)indoline-2,3-dione (**3**) 3.12 mmol and respective azides (**4A–E**) were dissolved in 20 mL of tertiary butanol. To the resulting solution, sodium ascorbate 1.24 mmol and copper sulphate pentahydrate (20 mL distilled water) 0.62 mmol were added and stirred for 5 h at 35 °C. Progress of reaction was monitored by TLC. After completion, the reaction mixture was extracted with ethyl acetate. Organic layer was separated and dried over anhydrous  $\text{Na}_2\text{SO}_4$ . Excess solvent was removed under vacuum and recrystallized from ethanol. MP: 163–165 °C; yield (%) 85; FT-IR KBr ( $\nu\text{ cm}^{-1}$ ): 3149, 3079, 2959, 1739, 1613, 1470, 1248;  $^1\text{H-NMR}$  (400 MHz,  $\text{DMSO}-d_6$   $\delta/\text{ppm}$ ): 8.13 (1H, s), 7.62–7.58 (1H, t,  $J = 15.6$  Hz), 7.54 (1H, d,  $J = 7.6$  Hz), 7.26 (2H, d,  $J = 11.2$  Hz), 7.14 (2H, t,  $J = 15.2$  Hz), 6.89 (2H, d,  $J = 8.8$  Hz), 5.44 (2H, s,  $-\text{CH}_2$ ), 4.92 (2H, s,  $-\text{CH}_2$ ), 3.70 (3H, s,  $-\text{OCH}_3$ ).

### 2.2. General procedure for synthesis of 1-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-3-hydrazonoindolin-2-one (6A–E)

1-((1-Benzyl-1H-1,2,3-triazole-4-yl)methyl)indoline-2,3-dione (**5A–E**) 1.0 mmol, and respective hydrazines ( $\text{R}_1\text{NHNH}_2$ ) were



Scheme 1 Synthesis of 3-substituted-1-((1-benzyl-1H-1,2,3-triazol-4-yl) methyl)indoline-2-one (**6Ab–Ed**).



refluxed in 50 mL absolute ethanol and 0.5 mL glacial acetic acid. The reaction mixture was cooled and, the precipitated mass of **6** was re-crystallized from the ethanol-chloroform mixture in appropriate ratio.

**2.2.1. 2-(1-((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl)-2-oxoindolin-3-ylidene)hydrazine carbothioamide (6Ab).** MP: 254–256 °C; yield (%) 65; FT-IR KBr ( $\nu$   $\text{cm}^{-1}$ ): 3410, 3150, 3055, 1692, 1613, 1469 & 1219;  $^1\text{H-NMR}$  (400 MHz, DMSO- $d_6$   $\delta$ /ppm): 12.37 (1H, s, -NH), 9.10 (1H, s), 8.75 (1H, s), 8.21 (1H, s), 7.72 (1H, d,  $J = 7.2$  Hz), 7.42–7.27 (6H, m), 7.18–7.12 (2H, m), 5.54 (2H, s, -N-CH<sub>2</sub>), 5.02 (2H, s, -N-CH<sub>2</sub>);  $^{13}\text{C NMR}$  (100 MHz, DMSO- $d_6$   $\delta$ /ppm): 179.15, 160.89, 142.83, 142.26, 136.33, 131.57, 131.43, 129.23, 128.65, 128.36, 124.28, 123.54, 121.26, 119.83, 110.84, 53.33, 35.05; HRMS (ESI) M + H for C<sub>19</sub>H<sub>17</sub>N<sub>7</sub>O<sub>5</sub>, calculated: 391.1215, observed: 392.1290.

**2.2.2. 1-((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl)-3-(2-phenylhydrazono)indolin-2-one (6Ac).** MP: 224–226 °C; yield (%) 55; FT-IR KBr ( $\nu$   $\text{cm}^{-1}$ ): 3437, 3181–3064, 2966, 2944, 1665, 1612, 1466 & 1245;  $^1\text{H-NMR}$  (400 MHz, DMSO- $d_6$   $\delta$ /ppm): 12.66 (1H, s, -NH), 8.18 (1H, s), 7.62 (1H, d,  $J = 6.8$  Hz), 7.47–7.26 (10H, m), 7.17–7.05 (3H, m), 5.54 (2H, s, -N-CH<sub>2</sub>), 5.07 (2H, s, -N-CH<sub>2</sub>);  $^{13}\text{C NMR}$  (100 MHz, DMSO- $d_6$   $\delta$ /ppm): 161.24, 142.83, 142.74, 140.33, 136.37, 130.00, 129.22, 128.82, 128.63, 128.37, 127.00, 124.07, 123.68, 123.03, 120.96, 118.93, 114.73, 110.29, 53.29, 34.78; HRMS (ESI) M + H for C<sub>24</sub>H<sub>20</sub>N<sub>6</sub>O, calculated: 408.1699, observed: 409.1780.

**2.2.3. 1-((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl)-3-(2-(5-chloro-6-oxo-1,6-dihydropyridazin-4-yl)hydrazono)indolin-2-one (6Ad).** MP: >300 °C; yield (%) 65; FT-IR KBr ( $\nu$   $\text{cm}^{-1}$ ): 3477, 3054, 2875, 1683, 1608, 1470 & 1270;  $^1\text{H-NMR}$  (400 MHz, DMSO- $d_6$   $\delta$ /ppm): 13.26 (1H, s, -NH), 12.92 (1H, s, -NH), 8.56 (1H, s), 8.24 (1H, s), 7.76 (1H, d,  $J = 10.4$  Hz), 7.43 (1H, t,  $J = 14.4$  Hz), 7.38–7.32 (3H, m), 7.29–7.27 (2H, m), 7.25 (1H, d,  $J = 8.4$  Hz), 7.18 (1H, t,  $J = 14.4$  Hz), 5.56 (2H, s, -N-CH<sub>2</sub>), 5.09 (2H, s, -N-CH<sub>2</sub>);  $^{13}\text{C NMR}$  (100 MHz, DMSO- $d_6$   $\delta$ /ppm): 161.50, 158.16, 142.29, 142.21, 140.97, 136.33, 134.55, 131.47, 129.23, 128.65, 128.38, 127.42, 124.29, 123.68, 119.48, 110.99, 109.84, 53.33, 35.03; HRMS (ESI) M + H for C<sub>22</sub>H<sub>17</sub>ClN<sub>8</sub>O<sub>2</sub>, calculated: 460.1163, observed: 461.1238.

**2.2.4. 2-(1-((1-(4-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2-oxoindolin-3-ylidene) hydrazinecarbothioamide (6Bb).** MP: 247–248 °C; yield (%) 50; FT-IR KBr ( $\nu$   $\text{cm}^{-1}$ ): 3420, 3085, 2989, 2934, 1679, 1607, 1490 & 1224;  $^1\text{H NMR}$  (400 MHz, DMSO- $d_6$   $\delta$ /ppm): 12.37 (1H, s, -NH), 9.11 (1H, s), 8.76 (1H, s), 8.22 (1H, s), 7.72 (1H, d,  $J = 7.2$  Hz), 7.44–7.38 (3H, m), 7.32 (2H, d,  $J = 8.4$  Hz), 7.18–7.11 (2H, m), 5.56 (2H, s, -N-CH<sub>2</sub>), 5.03 (2H, s, -N-CH<sub>2</sub>);  $^{13}\text{C NMR}$  (100 MHz, DMSO- $d_6$   $\delta$ /ppm): 179.15, 160.88, 142.82, 142.32, 135.30, 133.36, 131.57, 131.41, 130.35, 129.21, 124.34, 123.54, 121.26, 119.82, 110.83, 52.52, 35.03; HRMS (ESI) M + H for C<sub>19</sub>H<sub>16</sub>ClN<sub>7</sub>O<sub>5</sub>, calculated: 425.0826, observed: 426.0902.

**2.2.5. 1-((1-(4-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3-(2-phenylhydrazono)indolin-2-one (6Bc).** MP: 236–238–240 °C; yield (%) 65; FT-IR KBr ( $\nu$   $\text{cm}^{-1}$ ): 3310, 3069, 2983, 2938, 1661, 1594, 1469 & 1221;  $^1\text{H-NMR}$  (400 MHz, DMSO- $d_6$   $\delta$ /ppm): 12.68 (1H, s, -NH), 8.19 (1H, s), 7.62 (1H, d,  $J = 6.8$  Hz), 7.49 (2H, d,  $J = 8.8$  Hz), 7.44–7.38 (3H, m), 7.32–7.28 (3H, m), 7.18–7.06 (4H, m),

5.56 (2H, s, -N-CH<sub>2</sub>), 5.09 (2H, s, -N-CH<sub>2</sub>);  $^{13}\text{C NMR}$  (100 MHz, DMSO- $d_6$   $\delta$ /ppm): 161.24, 142.80, 140.32, 135.34, 133.35, 130.36, 130.01, 129.21, 128.84, 124.12, 123.69, 123.04, 120.95, 118.94, 114.73, 110.29, 52.49, 35.06, 34.06; HRMS (ESI) M + H for C<sub>24</sub>H<sub>19</sub>ClN<sub>6</sub>O, calculated: 442.1309, observed: 443.1386.

**2.2.6. 3-(2-(5-Chloro-6-oxo-1,6-dihydropyridazin-4-yl)hydrazono)-1-((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl) indolin-2-one (6Bd).** MP: 241–242 °C; yield (%) 65; FT-IR KBr ( $\nu$   $\text{cm}^{-1}$ ): 3423, 3067, 3032, 2983–2923, 1685, 1607, 1470 & 1226;  $^1\text{H-NMR}$  (400 MHz, DMSO- $d_6$   $\delta$ /ppm): 13.25 (1H, s, -NH), 12.91 (1H, s, NH), 8.56 (1H, s), 8.24 (1H, s), 7.76 (1H, d,  $J = 6.8$  Hz), 7.46–7.42 (3H, m), 7.32 (2H, d,  $J = 8$  Hz), 7.23–7.17 (3H, dt,  $J = 8.4, 15.2$  Hz), 5.57 (2H, s, -N-CH<sub>2</sub>), 5.09 (2H, s, -N-CH<sub>2</sub>);  $^{13}\text{C NMR}$  (100 MHz, DMSO- $d_6$   $\delta$ /ppm): 161.50, 158.17, 142.27, 140.97, 135.30, 134.54, 131.49, 130.37, 129.21, 127.42, 124.34, 123.70, 120.95, 119.48, 110.98, 109.84, 52.52, 35.02; HRMS (ESI) M + H for C<sub>22</sub>H<sub>16</sub>Cl<sub>2</sub>N<sub>8</sub>O<sub>2</sub>, calculated: 494.0733, observed: 495.0855.

**2.2.7. 2-(1-((1-(4-Methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2-oxoindolin-3-ylidene) hydrazinecarbothioamide (6Cb).** MP: 263–264 °C; yield (%) 60; FT-IR KBr ( $\nu$   $\text{cm}^{-1}$ ): 3413, 3060, 2920, 1685, 1612, 1489 & 1220;  $^1\text{H-NMR}$  (400 MHz, DMSO- $d_6$   $\delta$ /ppm): 12.37 (1H, s, -NH), 9.11 (1H, s), 8.76 (1H, s), 8.17 (1H, s), 7.71 (1H, d,  $J = 6.8$  Hz), 7.40 (1H, t,  $J = 15.2$  Hz), 7.19–7.09 (6H, m), 5.49 (2H, s, -N-CH<sub>2</sub>), 5.02 (2H, s, -N-CH<sub>2</sub>), 2.26 (3H, s, -CH<sub>3</sub>);  $^{13}\text{C NMR}$  (100 MHz, DMSO- $d_6$   $\delta$ /ppm): 179.16, 160.88, 142.84, 142.22, 138.03, 133.30, 131.56, 131.42, 129.75, 128.43, 124.09, 123.53, 121.25, 119.83, 110.84, 53.14, 35.05, 21.13; HRMS (ESI) M + H for C<sub>20</sub>H<sub>19</sub>N<sub>7</sub>O<sub>5</sub>, calculated: 405.1372, observed: 406.1465.

**2.2.8. 1-((1-(4-Methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3-(2-phenylhydrazono)indolin-2-one (6Cc).** MP: 216–217 °C; yield (%) 70; FT-IR KBr ( $\nu$   $\text{cm}^{-1}$ ): 3423, 3068, 2923, 1662, 1612, 1469 & 1221;  $^1\text{H-NMR}$  (400 MHz, DMSO- $d_6$   $\delta$ /ppm): 12.67 (1H, s, -NH), 8.14 (1H, s), 7.61 (1H, d,  $J = 7.2$  Hz), 7.54 (2H, d,  $J = 9.6$  Hz), 7.39 (2H, t,  $J = 15.2$  Hz), 7.30 (1H, t,  $J = 16.8$  Hz), 7.19–7.05 (7H, m), 5.49 (2H, s, -N-CH<sub>2</sub>), 5.07 (2H, s, -N-CH<sub>2</sub>), 2.26 (3H, s, -CH<sub>3</sub>);  $^{13}\text{C NMR}$  (100 MHz, DMSO- $d_6$   $\delta$ /ppm): 161.23, 142.83, 142.71, 140.33, 138.02, 133.35, 130.00, 129.74, 128.83, 128.44, 126.99, 123.88, 123.68, 123.03, 120.94, 118.93, 114.73, 110.29, 53.10, 34.77, 21.12; HRMS (ESI) M + H for C<sub>25</sub>H<sub>22</sub>N<sub>6</sub>O, calculated: 422.1855, observed: 423.1956.

**2.2.9. 3-(2-(5-Chloro-6-oxo-1,6-dihydropyridazin-4-yl)hydrazono)-1-((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl) indolin-2-one (6Cd).** MP: >300 °C; yield (%) 60; FT-IR KBr ( $\nu$   $\text{cm}^{-1}$ ): 3298, 3045, 2869, 1687, 1609, 1469 & 1270;  $^1\text{H-NMR}$  (400 MHz, DMSO- $d_6$   $\delta$ /ppm): 13.28 (1H, s, -NH), 12.90 (1H, s, -NH), 8.55 (1H, s), 8.19 (1H, s), 7.75 (1H, d,  $J = 6.0$  Hz), 7.42 (1H, t,  $J = 15.2$  Hz), 7.23–7.14 (6H, m), 5.49 (2H, s, -N-CH<sub>2</sub>), 5.07 (2H, s, -N-CH<sub>2</sub>), 2.26 (3H, s, -CH<sub>3</sub>);  $^{13}\text{C NMR}$  (100 MHz, DMSO- $d_6$   $\delta$ /ppm): 161.50, 158.17, 142.30, 142.17, 140.98, 138.04, 133.31, 131.48, 129.75, 128.45, 127.43, 124.10, 123.69, 120.94, 119.48, 109.83, 53.14, 35.03, 21.12; HRMS (ESI) M + H for C<sub>23</sub>H<sub>19</sub>ClN<sub>8</sub>O<sub>2</sub>, calculated: 474.1319, observed: 475.1425.

**2.2.10. 2-(1-((1-(4-Nitrobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2-oxoindolin-3-ylidene) hydrazinecarbothioamide (6Db).** MP: 277–278 °C; yield (%) 60; FT-IR KBr ( $\nu$   $\text{cm}^{-1}$ ): 3466,



3111, 3079, 2996, 2953, 1684, 1598, 1490, 1347 & 1222;  $^1\text{H-NMR}$  (400 MHz, DMSO- $d_6$   $\delta$ /ppm): 12.36 (1H, s, -NH), 9.13 (1H, s), 8.77 (1H, s), 8.29 (1H, s), 8.23 (2H, d,  $J = 9.2$  Hz), 7.72 (1H, d,  $J = 8.0$  Hz), 7.51 (2H, d,  $J = 8.4$  Hz), 7.41 (1H, t,  $J = 15.2$  Hz), 7.20–7.13 (2H, m), 5.74 (2H, s, -N-CH $_2$ ), 5.05 (2H, s, -N-CH $_2$ );  $^{13}\text{C}$  NMR (100 MHz, DMSO- $d_6$   $\delta$ /ppm): 179.16, 160.90, 147.71, 143.72, 142.82, 142.46, 131.58, 131.37, 129.51, 124.73, 124.37, 123.55, 121.25, 119.86, 110.85, 52.42, 35.06; HRMS (ESI) M + H for C $_{19}$ H $_{16}$ N $_8$ O $_3$ S, calculated: 436.1066, observed: 437.1143.

**2.2.11. 1-((1-(4-Nitrobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3-(2-phenylhydrazono)indolin-2-one (6Dc).** MP: 216–218 °C; yield (%) 65; FT-IR KBr ( $\nu$  cm $^{-1}$ ): 3433, 3074, 2978, 2942, 1664, 1597, 1467, 1520, 1350 & 1245;  $^1\text{H-NMR}$  (400 MHz, DMSO- $d_6$   $\delta$ /ppm): 12.68 (1H, s, -NH), 8.26 (1H, s), 8.23 (2H, d,  $J = 8.4$  Hz), 7.62 (1H, d,  $J = 6.8$  Hz), 7.54–7.46 (4H, m), 7.39 (2H, t,  $J = 16.4$  Hz), 7.31 (1H, t,  $J = 16.0$  Hz), 7.19–7.03 (3H, ddm,  $J = 7.2, 8$  Hz), 5.74 (2H, s, -N-CH $_2$ ), 5.10 (2H, s, -N-CH $_2$ );  $^{13}\text{C}$  NMR (100 MHz, DMSO- $d_6$   $\delta$ /ppm): 161.25, 147.70, 143.72, 142.93, 142.81, 140.30, 130.00, 129.50, 128.84, 126.97, 124.52, 124.35, 123.69, 123.04, 120.96, 118.94, 114.72, 110.28, 52.40, 34.77; HRMS (ESI) M – H for C $_{24}$ H $_{19}$ N $_7$ O $_3$ , calculated: 453.1549, observed: 452.1864.

**2.2.12. 3-(2-(5-Chloro-6-oxo-1,6-dihydropyridazin-4-yl)hydrazono)-1-((1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl)methyl)indolin-2-one (6Dd).** MP: >300 °C; yield (%) 60; FT-IR KBr ( $\nu$  cm $^{-1}$ ): 3130, 3046, 2974, 2841, 1685, 1609, 1470, 1349 & 1272;  $^1\text{H-NMR}$  (400 MHz, DMSO- $d_6$   $\delta$ /ppm): 13.26 (1H, s, -NH), 12.91 (1H, s, -NH), 8.55 (1H, s), 8.31 (1H, s), 8.23 (2H, d,  $J = 8.0$  Hz), 7.76 (1H, d,  $J = 8.0$  Hz), 7.51 (1H, d,  $J = 8.0$  Hz), 7.44 (2H, t,  $J = 15.2$  Hz), 7.26 (1H, d,  $J = 8.0$  Hz), 7.18 (1H, t,  $J = 18.4$  Hz), 5.75 (2H, s, -N-CH $_2$ ), 5.10 (2H, s, -N-CH $_2$ );  $^{13}\text{C}$  NMR (100 MHz, DMSO- $d_6$   $\delta$ /ppm): 162.89, 161.51, 158.16, 147.71, 143.69, 142.39, 142.27, 140.96, 134.52, 131.50, 129.52, 127.41, 124.74, 124.36, 123.71, 120.95, 119.49, 110.98, 109.86, 52.42, 35.03; HRMS (ESI) M – H for C $_{22}$ H $_{16}$ ClN $_9$ O $_4$ , observed: 505.1014, calculated: 504.0933.

**2.2.13. 2-(1-((1-(4-Methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2-oxoindolin-3-ylidene)hydrazinecarbothioamide (6Eb).** MP: 256–258 °C; yield (%) 60; FT-IR KBr ( $\nu$  cm $^{-1}$ ): 3419, 3127, 3067, 2999, 2962, 1676, 1613, 1467 & 1251;  $^1\text{H-NMR}$  (400 MHz, DMSO- $d_6$   $\delta$ /ppm): 12.36 (1H, s, -NH), 9.12 (1H, s), 8.77 (1H, s), 8.15 (1H, s), 7.71 (1H, d,  $J = 9.2$  Hz), 7.39 (1H, t,  $J = 15.2$  Hz), 7.27 (2H, d,  $J = 9.2$  Hz), 7.18–7.13 (2H, m), 6.91 (2H, d,  $J = 8.4$  Hz), 5.45 (2H, s, -N-CH $_2$ ), 5.01 (2H, s, -N-CH $_2$ ), 3.72 (3H, s, -OCH $_3$ );  $^{13}\text{C}$  NMR (100 MHz, DMSO- $d_6$   $\delta$ /ppm): 179.16, 160.88, 159.60, 142.84, 142.20, 131.57, 131.43, 130.06, 128.22, 123.91, 123.53, 121.25, 119.82, 114.57, 110.84, 55.59, 52.89, 35.05; HRMS (ESI) M + H for C $_{20}$ H $_{19}$ N $_7$ O $_2$ S, calculated: 421.1321, observed: 422.1401.

**2.2.14. 1-((1-(4-Methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3-(2-phenylhydrazono)indolin-2-one (6Ec).** MP: 198–200 °C; yield (%) 65; FT-IR ( $\nu$  cm $^{-1}$ ): 3202, 3064, 3021, 2971, 2956, 1669, 1613, 1469 & 1246;  $^1\text{H-NMR}$  (400 MHz, DMSO- $d_6$   $\delta$ /ppm): 12.67 (1H, s, -NH), 8.12 (1H, s), 7.61 (1H, d,  $J = 7.6$  Hz), 7.48 (2H, d,  $J = 7.2$  Hz), 7.39 (2H, t,  $J = 15.2$  Hz), 7.31–7.25 (3H, m), 7.18–7.05 (3H, m), 6.91 (2H, d,  $J = 8.0$  Hz), 5.45 (2H, s, -N-CH $_2$ ), 5.06 (2H, s, -N-CH $_2$ ), 3.72 (3H, s, -OCH $_3$ );  $^{13}\text{C}$  NMR (100 MHz, DMSO- $d_6$   $\delta$ /ppm): 161.23, 159.59, 142.83, 142.69, 140.34,

130.07, 130.00, 128.83, 128.26, 126.99, 123.03, 120.94, 118.93, 114.73, 114.56, 110.29, 55.58, 52.85, 34.77; HRMS (ESI) M + H for C $_{25}$ H $_{22}$ N $_6$ O $_2$ , calculated: 438.1804, observed: 439.1880.

**2.2.15. 3-(2-(5-Chloro-6-oxo-1,6-dihydropyridazin-4-yl)hydrazono)-1-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)indolin-2-one (6Ed).** MP: >300 °C; yield (%) 70; FT-IR ( $\nu$  cm $^{-1}$ ): 3298, 3210, 2954, 1678, 1609, 1468 & 1255;  $^1\text{H-NMR}$  (400 MHz, DMSO- $d_6$   $\delta$ /ppm): 13.26 (1H, s, -NH), 12.90 (1H, s, -NH), 8.55 (1H, s), 8.18 (1H, s), 7.75 (1H, d,  $J = 7.6$  Hz), 7.44 (1H, t,  $J = 16.0$  Hz), 7.30–7.22 (3H, m), 7.17 (1H, t,  $J = 15.2$  Hz), 6.91 (2H, d,  $J = 8.8$  Hz), 5.46 (2H, s, -N-CH $_2$ ), 5.06 (2H, s, -N-CH $_2$ ), 3.72 (3H, s, -OCH $_3$ );  $^{13}\text{C}$  NMR (100 MHz, DMSO- $d_6$   $\delta$ /ppm): 161.49, 159.60, 158.17, 142.31, 142.16, 140.98, 134.55, 131.48, 130.08, 128.22, 127.43, 123.92, 123.68, 120.94, 119.48, 114.57, 110.98, 109.83, 55.59, 52.89, 35.03; HRMS (ESI) M + H for C $_{23}$ H $_{19}$ ClN $_8$ O $_3$ , calculated: 490.1269, observed: 491.1142.

## 2.3. Biological investigation

**2.3.1. Cancer cell lines.** The human cancer cell lines Capan-1, HCT-116, NCI-H460, LN-229, HL-60, K-562, MOLT4, Z-138 and HEK293 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The DND-41 cell line was sourced from the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ Leibniz-Institut, Braunschweig, Germany). All cell lines were cultured according to the suppliers' recommendations. Culture media were purchased from Gibco (Gibco Life Technologies, Merelbeke, Belgium) and supplemented with 10% fetal bovine serum (HyClone, Cytiva, MA, USA). For all biological assays, the test compounds and reference drugs were dissolved in DMSO at a concentration of 100  $\mu\text{M}$ .

**2.3.2. Cytotoxicity assays.** Adherent cell lines were seeded at densities ranging from 500 to 1500 cells per well in 384-well plates (Greiner Bio-One, Vilvoorde, Belgium). Following overnight incubation, cells were treated with seven different concentrations of the test compounds, ranging from 100 to 0.006  $\mu\text{M}$ . Untreated cell lines (*i.e.*, without compound treatment) were used as negative controls.

Suspension cell lines were seeded at densities ranging from 2500 to 5000 cells per well in 384-well culture plates containing the test compounds at the same concentration points. All cell lines were incubated for 72 h with compounds and then analyzed using the CellTiter 96<sup>®</sup> AQueous One Solution Cell Proliferation Assay (MTS) reagent (Promega, Leiden, The Netherlands) according to the manufacturer's instructions. Absorbance of the samples was measured at 490 nm using a SpectraMaxPlus 384 (Molecular Devices, CA, USA), and OD values were used to calculate the 50% inhibitory concentration (IC $_{50}$ ). Compounds were tested in two independent experiments.<sup>35</sup>

**2.3.3. GSK3 $\beta$  kinase assay using ADP-Glo.** A reaction mixture of 25  $\mu\text{L}$  was prepared in a 96-well plate, consisting of 5X reaction buffer, 50  $\mu\text{M}$  ATP, 50  $\mu\text{M}$  DTT, 1  $\mu\text{g}$  per  $\mu\text{L}$  GSK3 $\beta$  substrate, and 0.5 ng per  $\mu\text{L}$  GSK-3 $\beta$  enzyme (Catalognumber: V1991 Promega), along with increasing concentrations of the compounds **6Eb** and **6Ec**. A reaction mixture containing DMSO



served as the vehicle control, while 12 nM laduviglusib was used as a positive control for the experiment. The reaction was incubated at room temperature for 60 min. Following incubation, 5  $\mu$ L of ADP-Glo TM Reagent (Catalog number: V6930, Promega) was added and the mixture was incubated at room temperature for an additional 40 min. Subsequently, 10  $\mu$ L of kinase detection reagent was added, and the mixture was incubated at room temperature for 30 min. Luminescence was measured using a plate-reader with an integration time of 0.25 to 1 second.

**2.3.4. Western blotting.** Compounds **6Eb**, **6Ec** treated and control cells were harvested and lysed in RIPA buffer (1 M Tris pH 8, 1% Triton X-100, 0.5% sodium deoxycholate, 1% sodium chloride, 0.1% SDS, 1 mM sodium orthovanadate) supplemented with a protease inhibitor cocktail from MP Biomedicals. The total protein concentration was determined using the Bradford method, and 35  $\mu$ g of protein was resolved by SDS-PAGE before being transferred to a PVDF membrane. The membrane was cut and probed with the appropriate antibodies. The antibody concentrations were as follows: GAPDH (BioLegend) at 1 : 5000, NF- $\kappa$ B (BioLegend) at 1 : 1000, PTEN (CST) at 1 : 1000, STAT-3 (CST) at 1 : 1000,  $\beta$ -catenin at 1 : 1000. Anti-rabbit IgG-HRP (CST) at 1 : 1000, and anti-mouse-IgG-HRP (CST) at 1 : 5000 and 1 : 1000. Protein bands were visualised using the enhanced chemiluminescence substrate from Bio-Rad. Images were captured on the Bio-Rad Doc.

## 2.4. Computational (*in silico*) study

**2.4.1. Docking protocol.** The protein–ligand interactions were performed using the PyRx software (version 0.8) using AutoDockVina. The docking method had previously been established.<sup>36,37</sup> In brief, GSK-3 $\beta$  receptor protein (PDB ID: 1Q41) was extracted from the Protein Data Bank (PDB). The ligand structures were drawn using ChemDraw Ultra 12 and modified in 3D conformers. The protein was treated before being saved in PDBQT format, which included eliminating excess metals and water, reducing energy, and introducing hydrogen to the native ligand. The ligand was altered by reducing its energy content level and introducing Gasteiger charges and polar hydrogen. The file was saved using PDBQT, with active torsion set to 6. The grid box for GSK-3 $\beta$  was created using centre attributes ( $X = 39.65$ ,  $Y = 6.22$ ,  $Z = 37.53$ ) and size ( $X = 25$ ,  $Y = 25$ , and  $Z = 25$ ). The number of conformers was set at ten with an exhaustiveness of eight. The Discovery Studio Visualization software (version 4) was used to view the interaction. The docking scores were captured, and the 3D contact photos were stored as JPG files.

**2.4.2. Molecular dynamics simulation studies.** The DESMOND software (Schrodinger Release 2021-3; DE Shaw Research, New York; academic license) was used to evaluate molecular dynamics of the best docked protein–ligand combination. This study used the Berendsen thermostat and barostat procedures for 100 ns. The system was resolved, reduced, and stored in a TIP3P. The Desmond package for protein production, ligand preparation, and Epik tools all validated the correctness of molecular structures. Physiological states were

mimicked by neutralizing the solvated complex system with suitable Na<sup>+</sup>/Cl<sup>-</sup> counterions at a salt concentration of 0.15 M using an optimum potential for liquid simulations (OPLS) all-atom force field (at 300 K and 1.01325 bars). To relax the system, the Broyden–Fletcher–Goldfarb–Shanno and steepest descent algorithms were used. The Nose–Hoover thermostat and Martyna–Tobias–Klein barostat algorithms were used in the dynamics simulation at 300 K (Kelvin) and 1 atm. (atmospheric) pressure. The smooth particle mesh Ewald technique was used to manage both long-range and short-range coulombic interactions, using 9 Å endpoint values. MD simulations were performed for 100 ns, with data on trajectory recorded for the remaining 2 ns. The stability of the bound complexes **6Ec-1Q41** and **bioacetoxime-1Q41** was assessed using root mean square deviation (RMSD).<sup>37</sup>

**2.4.3. MM-GBSA calculations.** The binding free energies of the GSK-3 $\beta$  protein (1Q41), **6Ec**, and standard (bioacetoxime) complex were examined using the molecular mechanics-generalized born surface area (MM-GBSA) methodology and the prime module's Python script called MMPBSA.py.<sup>38,39</sup> The binding free energy was calculated using the OPLS 2005 force field, the VSGB solvent model, and the rotamer search method.<sup>40</sup> The following eqn (1) was used to compute the binding free energy of ligands with the GSK-3 $\beta$  receptor:

$$\Delta G_{\text{bind}} = G_{\text{complex}} - (G_{\text{protein}} + G_{\text{ligand}}) \quad (1)$$

where  $\Delta G_{\text{bind}}$  = binding free energy,  $G_{\text{complex}}$  = free energy of the complex,  $G_{\text{protein}}$  = free energy of the target protein, and  $G_{\text{ligand}}$  = free energy of the ligand.

**2.4.4. Density functional theory (DFT) calculations on **6Ec** molecule.** The theoretical computations were performed using the DFT method to calculate properties like chemical potential ( $\mu$ ), hardness ( $\eta$ ), softness ( $S$ ), electrophilicity index ( $w$ ), and electronegativity ( $c$ ). Molecular electrostatic potential and frontier molecular orbitals were analyzed using optimized geometry of the studied compound (**6Ec**). All DFT calculations were carried out using the Gaussian 16 program, taking hybrid Becke's three parameters (B3) with a Lee–Yang–Par (LYP) correlation functional (B3LYP) and a 6-31G(d) basis set. GaussView 6.1 interface program was used to visualize three-dimensional structures and to prepare input files for Gaussian.<sup>41</sup>

**2.4.5. ADME/toxicity prediction.** Molecular descriptors commonly used in absorption, distribution, metabolism, and elimination (ADME) analysis were calculated using the Swiss-ADME web server.<sup>42,43</sup>

## 3. Results and discussion

### 3.1. Chemistry

A total of fifteen indole linked 1,2,3-triazoles (**6Ab–Ed**) were prepared by reacting 1.0 mmol of 1-((1-benzyl-1*H*-1,2,3-triazole-4-yl)methyl)indoline-2,3-dione (**5A–E**), and respective hydrazines (R<sub>1</sub>NHNH<sub>2</sub>). All structures were confirmed for their structure by FTIR, <sup>1</sup>H/<sup>13</sup>C NMR and, HRMS data. In the FT-IR spectra of synthesized derivatives (**6Ab–6Ed**), the indole-NH



**Table 1** Cytotoxic effects of the compounds on Capan-1, HCT-116, LN229, NCI-H460, DND-41, HI-60, K562 & Z138 cells. Results are presented as mean  $\pm$  standard deviation of two independent experiments

Compounds	Cytotoxicity adherent cells (CC <sub>50</sub> ) 100 $\mu$ M				Cytotoxicity suspension cells (CC <sub>50</sub> ) 100 $\mu$ M			
	Capan-1	HCT-116	LN229	NCI-H460	DND-41	HI-60	K562	Z138
<b>6Ab</b>	>100	>100	>100	>100	>100	>100	>100	>100
<b>6Ac</b>	>100	>100	>100	>100	>100	>100	>100	>100
<b>6Ad</b>	>100	>100	>100	>100	>100	>100	>100	>100
<b>6Bb</b>	>100	54.05 $\pm$ 0.71	>100	>100	>100	>100	>100	>100
<b>6Bc</b>	>100	>100	>100	>100	>100	>100	>100	>100
<b>6Bd</b>	74.30 $\pm$ 0.28	>100	>100	>100	>100	>100	>100	>100
<b>6Cb</b>	41.95 $\pm$ 2.33	70.70 $\pm$ 3.25	12.55 $\pm$ 0.78	>100	>100	>100	>100	>100
<b>6Cc</b>	62.15 $\pm$ 7.28	>100	70.85 $\pm$ 10.96	>100	>100	>100	>100	>100
<b>6Cd</b>	>100	>100	>100	>100	>100	>100	>100	>100
<b>6Db</b>	>100	>100	23.55 $\pm$ 1.91	>100	>100	>100	>100	>100
<b>6Dc</b>	26.10 $\pm$ 3.82	>100	>100	>100	>100	>100	>100	>100
<b>6Dd</b>	>100	>100	>100	>100	>100	>100	>100	>100
<b>6Eb</b>	9.40 $\pm$ 0.57	46.30 $\pm$ 6.22	10.20 $\pm$ 0.99	>100	>100	>100	>100	>100
<b>6Ec</b>	8.25 $\pm$ 0.78	34.25 $\pm$ 5.16	67.90 $\pm$ 1.70	>100	73.80 $\pm$ 14.42	76.05 $\pm$ 3.75	88.85 $\pm$ 10.25	53.80 $\pm$ 2.12
<b>6Ed</b>	>100	>100	>100	>100	>100	>100	>100	>100
Sunitinib	1.5 $\pm$ 0.01	4.25 $\pm$ 0.71	11.80 $\pm$ 1.41	8.85 $\pm$ 3.04	12.90 $\pm$ 1.98	5.00 $\pm$ 1.27	8.4 $\pm$ 2.12	8.15 $\pm$ 1.49
5-Fluorouracil	2.7 $\pm$ 0.01	2.3 $\pm$ 0.71	7.35 $\pm$ 0.35	5.00 $\pm$ 1.70	65.35 $\pm$ 4.60	5.90 $\pm$ 0.99	12.90 $\pm$ 0.42	7.85 $\pm$ 0.71

stretching peaks appeared between 3477–3130  $\text{cm}^{-1}$  while, the aromatic and aliphatic  $-\text{CH}$  stretching were observed in the range of 3210–3021 and 2999–2841  $\text{cm}^{-1}$  respectively. Intense peaks for carbonyl ( $\text{C}=\text{O}$ ) stretching appeared between 1692–1661  $\text{cm}^{-1}$ . In  $^1\text{H-NMR}$  spectra of **6Ab–Ed** the  $-\text{NH}$  protons appeared between  $\delta$  13.88–12.26 ppm. Aromatic protons observed in the range of  $\delta$  9.38–6.84 ppm. Peaks for  $-\text{CH}_2$  protons appeared between  $\delta$  5.75–5.01 ppm. The methoxy protons ( $-\text{OCH}_3$ ) of **6Eb**, **6Ec** & **6Ed** appeared at  $\delta$  3.72 ppm. The methyl protons ( $-\text{CH}_3$ ) of **6Cb**, **6Cc** & **6Cd** appeared at  $\delta$  2.26 ppm. The  $^{13}\text{C}$  NMR spectra of all molecules had shown peak for  $\text{C}=\text{S}$  at  $\delta$  179 ppm, between  $\delta$  162.89 to 160.88 ppm for  $\text{C}=\text{O}$ , and between  $\delta$  159.60 to 109.83 ppm for aromatic carbons, at  $\delta$  55.89 ppm for  $\text{OCH}_3$  and between  $\delta$  53.33 to 34.77 ppm for  $-\text{N}-\text{CH}_2$ , at  $\delta$  21.13 ppm for  $\text{CH}_3$  carbons. The  $m/z$  values of all molecules (**6Ab–Ed**) were found in close proximity with calculated mass of the molecule and confirming their structure.

### 3.2. Cytotoxicity study

The cytotoxicity studies in a series of hydrazide-2-oxindole analogues (**6Ab–Ed**) carried out across a broad range of human cancer cell lines include Pancreatic adenocarcinoma (Capan-1), Colorectal carcinoma (HCT-116), Glioblastoma (LN229), Lung carcinoma (NCI-H460), Acute lymphoblastic leukaemia (DND-41), Acute myeloid leukaemia (HI-60), Chronic myeloid leukaemia (K562), T lymphoblast (MOLT4), Non-Hodgkin lymphoma (Z138) and normal human embryonic kidney (HEK 293) cell lines. Sunitinib and 5-Fluorouracil were used as reference standard during the study. In comparison to sunitinib (1.5  $\mu\text{M}$ ) and 5-fluorouracil (2.7  $\mu\text{M}$ ), molecules **6Eb** and **6Ec** exhibited moderate cytotoxicity specifically against Capan-1 cells with  $\text{IC}_{50}$  values in the range of 8.25–9.40  $\mu\text{M}$  indicating some level of cytotoxicity over other molecules in the series. Two

more compounds namely **6Cb** and **6Eb** showed cytotoxicity against LN229 cells ( $\text{CC}_{50}$ : 10.20–12.55  $\mu\text{M}$ ). The compounds **6Eb** and **6Ec** displayed promising toxicity against MOLT4 cells with 2.7 and 0.9  $\mu\text{M}$  respectively (ESI Fig. 1†). Rest of the molecules failed to exhibit significant cytotoxicity against tested human cancer cell lines. To test these compounds toxicity on normal cells, both **6Eb** and **6Ec** were tested on HEK 293 cells and found to be non-toxic with  $\text{IC}_{50}$  46  $\mu\text{M}$  and 144  $\mu\text{M}$  respectively. These results indicate that these two molecules are non-toxic to normal cells with the great selectivity to cancer cells. The study suggests that the substituent on the triazole benzyl ring (specifically  $-\text{H}$  or electron donating  $\text{CH}_3$  and 4- $\text{OCH}_3$ ) and the carbothiamide and pridazinone substitutions on the hydrazide nitrogen are critical in the observed cytotoxicity by **6Cb**, **6Eb** and **6Ec**. Based on cytotoxicity data we can conclude that specific substituents other than  $-\text{H}$  or methyl and methoxy became potent cytotoxic compounds, particularly against the Capan-1 and LN229 cells. Further, despite the moderate activity of **6Cb**, **6Eb** against LN229, & **6Eb**, **6Ec** against Capan-1 cells, none of the derivatives exhibited notable cytotoxicity against other cancer cell lines suggesting, a certain degree of selectivity for LN229 and Capan-1 cells. Overall these compounds are selectively potent against adherent type cancer cell lines tested but not to suspension type cancer cell lines (Table 1).

### 3.3. Inhibition study of GSK-3 $\beta$ kinase

A kinase activity experiment was conducted in the presence of inhibitors to determine their specificity for GSK-3 $\beta$ . A reaction mixture containing 50  $\mu\text{M}$  ATP, 50  $\mu\text{M}$  DTT, 1  $\mu\text{g}$  per  $\mu\text{L}$  GSK-3 $\beta$  substrate, and 0.5 ng per  $\mu\text{L}$  GSK3 $\beta$  enzyme, together with increasing quantities of the **6Eb** and **6Ec** (1  $\mu\text{M}$  to 125  $\mu\text{M}$ ), was incubated. The reaction mixture including DMSO served as the vehicle control, whereas 12 nM laduviglusib was employed as a positive control in the experiment. At sub-micromolar






Fig. 3 The figure illustrates the dose–response relationship of compounds **6Eb** and **6Ec** in inhibiting GSK-3 $\beta$  activity. (A) Effect of compound **6Eb**, at a broad range assay. (B) Effects of compound **6Ec**, at a broad range. (C) Effect of compound **6Eb**, at a narrower range. Data are presented as mean  $\pm$  SDM. Significance was plotted based on  $p$  values and denoted as \* ( $p$ -value  $\leq$  0.05), \*\* ( $p$ -value  $\leq$  0.01), \*\*\* ( $p$ -value  $\leq$  0.001), \*\*\*\* ( $p$ -value  $\leq$  0.0001) and ns as not significant.

concentrations, GSK-3 $\beta$  inhibitors reduced their efficacy by 50%. Specifically, **6Eb** exhibited 50% inhibition of activity at a concentration of  $11.02 \pm 1.95 \mu\text{M}$ . The activity of **6Eb** was 60%,

50%, and 40% at concentrations of 5  $\mu\text{M}$ , 7.5  $\mu\text{M}$ , and 10  $\mu\text{M}$ , respectively. These observations suggest that **6Eb** decreased the activity of GSK-3 $\beta$  in a concentration-dependent manner. While




Fig. 4 GSK-3 $\beta$  inhibitors induced alterations in MOLT4 cells: (A) western blot analysis of GSK-3 $\beta$  targets **6Eb** (GSKi) (A) treated MOLT4 cells lysates and **6Ec** (B) and corresponding quantitation (i, ii, iii) of NF- $\kappa$ B,  $\beta$ -catenin and PTEN. Each experiment was done in duplicates, and a representative image is shown for each marker. Quantification was done for each marker (i, ii, iii) and is represented as a bar graph of mean  $\pm$  SEM. One sample  $t$ -test and one way ANOVA test was performed, and the  $p$ -value were calculated between control, and compounds treated groups (\*:  $p$ -value  $<$  0.05).



compound **6Ec** showed a 50% inhibition at higher values of  $59.81 \pm 7.56 \mu\text{M}$  (Fig. 3A–C). These investigations suggest that our designed compounds acted as anticancer agents *via* inhibition of GSK-3 $\beta$ .

### 3.4. **6Eb** regulated GSK-3 $\beta$ targets NF- $\kappa$ B and $\beta$ -catenin

To check the activity of the GSK-3 $\beta$  inhibitors in cells, MOLT4 cells were treated with varying concentrations of **6Eb** and **6Ec** and the  $\text{IC}_{50}$  was calculated based on MTT assay (ESI Fig. 1a and b†). In MOLT4 cells,  $\text{IC}_{50}$  for **6Eb** and **6Ec** was 2.7 and 0.9  $\mu\text{M}$  respectively, which was lowest among all the cell lines screened for GSK-3 $\beta$  inhibitor. We performed western blot for select GSK-3 $\beta$  targets, NF $\kappa$ B,  $\beta$ -catenin and PTEN. **6Eb** showed downregulation of NF- $\kappa$ B, upregulation of  $\beta$ -catenin and no change in PTEN levels. It is very well known that phosphorylation of  $\beta$ -catenin by GSK-3 $\beta$  leads to ubiquitin mediated

destruction of  $\beta$ -catenin, therefore inhibition led to an increase in  $\beta$ -catenin. Upregulation of  $\beta$ -catenin and downregulation of NF- $\kappa$ B lead to increase in cytotoxicity upon GSK-3 $\beta$  inhibitor. **6Ec** did not show any change in the levels of any of the proteins tested (Fig. 4). To check whether **6Ec** downregulated any of the GSK-3 $\beta$  target, we selected STAT3 (ESI Fig. 2a and b†), and found downregulation of STAT3 in **6Eb** and not **6Ec**, which is also evident from the kinase assay suggesting low kinase inhibitor activity of **6Ec**, although higher cytotoxicity was observed with **6Ec**.

### 3.5. *In silico* study

**3.5.1. Molecular docking studies.** The most potent compounds in biological screening, **6Eb** and **6Ec**, were picked out and docked to study how indole derivatives interact with GSK-3 $\beta$ . The docking protocol was validated by re-docking the




Fig. 5 Docking interaction images of **6Eb** against GSK-3 $\beta$ : (A) 3D view, (B) 2D view, (C) 3D hydrophobic surface view; H-bond denoted by green dashed line, pink and gray dashed line-lipophilic contacts, orange dashed line-pi-cation interaction.



co-crystal ligand back to the target. The RMSD between the co-crystal ligand and the observed pose was 0.62 Å, indicating that the docking protocol is accurate to evaluate the interaction. In the study, the docking scores of molecules **6Eb**, **6Ec**, and **bio-acetoxime** were  $-10.5$  kcal mol $^{-1}$ ,  $-8.8$  kcal mol $^{-1}$ , and  $-7.7$  kcal mol $^{-1}$ , respectively. The binding pocket contains Pro214, Ala231, Ala160, Leu194, Val147, Leu210, Lys162, Ala273, Leu215, Arg137, Gly218, Leu139, Thr217, Glu260, and Gly216. The thiourea side chain of compound **6Eb** developed two strong hydrogen bonds and a pi-cation contact with Asp200. Furthermore, the *p*-methoxyphenyl ring developed several lipophilic bonds with Ile60, Val70, Val110, Ala83, Leu132, Leu132, and Cys199, firmly holding the enzyme from the ends and aiding in filling the expanded cavity. In addition, the triazole ring stabilized the kinase from the middle by interacting with Ile62 in

a lipophilic way. The indole ring also helped to stabilize the protein–ligand complex by interacting with Cys199 in a lipophilic way.

There were strong lipophilic interactions between the phenylhydrazone ring of compound **6Ec** and Ala83, Val110, Leu132, and Leu188 at the end of the kinase. These numerous interactions keep the molecule in a stable shape and stabilize the ligand–protein combination. A *p*-methoxyphenyl ring connected the kinase with Ile62 *via* lipophilic contacts at its extremities. The ketone of the indole ring also improved the stability of the complex through H-bonds and lipophilic interactions with Cys199 and Val70. Furthermore, the indole ring increased binding affinity by supporting the kinase from the center *via* a significant multiple pi-cation interaction with Asp200. The binding and stability of the protein–ligand




Fig. 6 Docking interaction images of **6Ec** against GSK-3 $\beta$ : (A) 3D view, (B) 2D view, (C) 3D hydrophobic surface view; H-bond denoted by green dashed line, pink and gray dashed line–lipophilic contacts, orange dashed line–pi-cation interaction.






Fig. 7 Docking interaction images of bio-acetoxime (standard) against GSK-3 $\beta$ : (A) 3D view, (B) 2D view; H-bond denoted by green dashed line, pink and gray dashed line-lipophilic contacts, orange dashed line-pi-cation interaction.

complex to GSK-3 $\beta$  were significantly influenced by many interactions, including pi-cation interactions, lipophilic contact, and H-bonds. These findings align with their biological

investigation, indicating that compound **6Ec** exhibited anti-cancer effects through GSK3 $\beta$  inhibition.

The replacement of a smaller linkage of hydrazinecarbothioamide with phenylhydrazide in **6Ec** changed the orientation




Fig. 8 RMSD and RMSF plots. (A and C) compound **6Ec**-GSK-3 $\beta$ ; (B and D) bio-acetoxime-GSK-3 $\beta$ .




Fig. 9 Protein–ligand contact and timeline plot. (A and C) compound **6Ec**-GSK-3 $\beta$ ; (B and D) **bio-acetoxime**-GSK-3 $\beta$ .

within the pocket, but it retained binding with comparable residues. These changes in **6Ec** could be attributed to the presence of two bulky phenyl rings, such as *p*-methoxyphenyl and phenylhydrazide, on both sides of the molecule. In contrast, **6Eb** had an aliphatic part of hydrazinecarbothioamide on one side and *p*-methoxyphenyl on the other. The change in the substitution pattern causes both compounds to orientate differently within the same pocket occupied by standard.

In the **bio-acetoxime**, the ketone group at the second position of indole formed strong hydrogen bonds with Lys85 and Asp200. The presence of bromine at the C6 position of indole increased lipophilic interactions with Ala83, Tyr134, and Leu188. Furthermore, indole showed many lipophilic and pi-cation interactions with Val70 and Leu188 and Cys199, respectively. Furthermore, strong pi-cation interactions between the indole ring and Asp200 were observed, stabilizing the protein–

ligand complex from one end. The images in (Fig. 5–7) demonstrated that our developed compounds bind to residues and binding sites similar to those of the standard. Moreover, their higher docking score indicates that these compounds could act as an anticancer agent by targeting GSK-3 $\beta$ .

**3.5.2. Molecular dynamic simulation study.** The molecular dynamics technique was utilized to look into the stability and conformational changes of molecules in the simulated protein. Compound **6Ec** had stronger cytotoxicity, a higher docking score, and a promising ADME/Tox profile. These findings suggest investigating the GSK-3 $\beta$  protein-bound complex of **6Ec** for molecular dynamics simulation in comparison to **bio-acetoxime** (standard). The stability of the complexes was assessed using potential energy throughout a 100-ns simulation time with a 2-ns interval. This study examined the stability of protein–ligand complexes using RMSD graphs.

Table 2 Post simulation binding energy analysis (MM/GBSA) of compound **6Ec** and **bio-acetoxime**

Compound	$\Delta G_{\text{bind}}$	$\Delta G_{\text{bindLipo}}$	$\Delta G_{\text{bindvdW}}$	$\Delta G_{\text{bindCoulomb}}$	$\Delta G_{\text{bindHbond}}$	$\Delta G_{\text{bindSolvGB}}$	$\Delta G_{\text{bindCovalent}}$
<b>6Ec</b>	−66.019	−27.785	−59.977	−12.463	−1.433	14.968	−4.068
<b>Bio-acetoxime</b>	−49.204	−15.185	−45.547	−22.258	−1.572	13.730	−2.151



Root Mean Square Deviation (RMSD) is a measure of how far atoms move from one frame to another. During simulation, the RMSD of the protein and ligand can reveal structural conformation and ligand stability in relation to the protein and binding site. Changes of 1–3 Å are suitable for small and globular proteins.<sup>37</sup> Compound **6Ec** and protein stabilized after modest alterations over the first 15 ns of MD simulation. After a brief period of drifting (17–19 ns), it returned and remained steady for the following 31 ns. Between 32–37 ns and 40–41 ns, there was another drift away from the complex with minor fluctuations. After 43 ns, it stayed connected to the protein for the remainder of the simulation session. The RMSD value for compound **6Ec** and GSK-3 $\beta$  was 1 Å, which falls within the acceptable range of 1–3 Å, demonstrating stability (Fig. 8A and B).

The RMSD plot of the target GSK-3 $\beta$  with the bound ligand **bio-acetoxime** (standard) in (Fig. 8B) demonstrated that the ligand–protein complex was stable within the first 5 ns, with a minor fluctuation at a distance of 3.0 Å. Despite moving away from the protein for 37–68 ns, the ligand returned to its original position and remained fixed until the simulation was over. The RMSD value for target GSK-3 $\beta$  with standard was around 1.0 Å, which is within acceptable limits (1–3 Å).

**3.5.3. The root mean square fluctuations (RMSF).** The RMSF graph shows protein amino acid residue fluctuations over simulation time. Modifications of 1–3 Å are appropriate for small and globular proteins.<sup>38</sup> Compound **6Ec** (Fig. 8C and D) had lower RMSF values in the system (0.6–3 Å). Its residues 25 and 240 exhibited the highest peaks at 3 Å, indicating significant fluctuation in some regions, whereas the rest were below 2.4 Å. The standard's fluctuation ranged from 0.6 to 4.8 Å, which was higher than 3 Å. In comparison to compound **6Ec**, the peaks were substantially higher and reached 4.8 Å, indicating increased variance in specific regions. Furthermore, the **bio-acetoxime** (standard) showed steeper and higher-frequency peaks, indicating greater variability in certain residues. The spike around residues 60 and 240 was significantly greater than the rest, indicating instability or flexibility in that region. These findings suggest that **6Ec** did not significantly affect the protein's structure and organization upon binding.

**3.5.4. Protein–ligand contacts.** Compound **6Ec** had strong to moderate protein–ligand interactions, with interaction percentages as high as 0.6 (Fig. 9A and B). It formed a strong hydrogen bond with Asn64 for 35% of the simulation duration and a weak H-bond with Val135. Moreover, **6Ec** and the **bio-acetoxime** (standard) engaged in lipophilic interactions with similar residues such as Phe67, Val70, Ala83, and Leu188, which accounted for 60%, 30%, 50%, and 30% of the total occupancy. Furthermore, **6Ec** had a strong 40% water-mediated H bridge with Ile62, whereas the standard had less than 10% time. Standard also had a strong H-bond and water bridge with Val135 50% of the time, with a fraction of 1% interaction. This demonstrates that certain protein residues may interact with the ligand multiple times using the same subtype. It also created weak hydrogen bonds with Ile62, Lys85, and Cys199. Both **6Ec** and **bio-acetoxime** (standard) demonstrated a concentrated pattern of interaction over many residues. These




Fig. 10 Ground state optimized and labeled structures of **6Ec** were calculated using DFT/B3LYP/6-31G(d) level of theory.

findings reveal that **6Ec** had a comparable binding pattern to the standard, implying that our developed compound had an affinity against the target protein.

**3.5.5. Protein–ligand timeline contacts.** The interaction and contact timeline (H-bonds, hydrophobic, ionic, and water bridges) are summarized in (Fig. 9C and D). The top panel displays the total number of individual interactions the protein had with the ligand **6Ec** during the 100 ns MD simulation trajectory. The bottom panel displays the residues that interact with the ligand in each trajectory frame. Some residues, especially Ile62, Asn64, Phe67, Val70, Ala83, and Leu188 in **6Ec**, and Phe67, Ala83, and Val135 in the **bio-acetoxime** (standard), demonstrated more than one unique interaction with the ligand, as indicated by a darker orange shading on the plot's scale on the right. In the docking analysis of **6Ec**, the residues Ile62, Val70, Ala83, and Leu188 also contributed significantly to binding. These findings are consistent with their important role in a protein–ligand contact study.

**3.5.6. MM-GBSA study.** The MM-GBSA approach is often used to determine the binding free energy of a ligand to a protein molecule.<sup>38</sup> The binding free energy of the **6Ec**-GSK-3 $\beta$  and **bio-acetoxime**-GSK-3 $\beta$  complexes were determined, along with the impact of various non-bonded interaction energies (Table 2). The complex **6Ec** GSK-3B had a binding energy of  $-66.019$  kcal mol<sup>-1</sup>, which was 1.34 times lower than the **bio-acetoxime** (standard) complex ( $-49.204$  kcal mol<sup>-1</sup>). Non-bonded interactions, including  $\Delta G_{\text{bindLipo}}$ ,  $\Delta G_{\text{bindCovalent}}$ ,  $\Delta G_{\text{bindHbond}}$ ,  $\Delta G_{\text{bindCoulomb}}$ ,  $\Delta G_{\text{bindSolvGB}}$ , and  $\Delta G_{\text{bindvdW}}$ , affect the binding free energy of  $\Delta G_{\text{bind}}$ . In all types of interactions,  $\Delta G_{\text{bindvdW}}$  and  $\Delta G_{\text{bindLipo}}$  were significantly lower in energy than standard and contributed the most to average binding energy in protein–ligand interactions (Table 2). Also,

Table 3 Optimization energy and dipole moment of compound **6Ec**

Compound	Optimisation energy (hartree)	Dipole moment (debye)
<b>5Ec</b>	-1444.826	3.709






Fig. 11 Frontier molecular orbitals (HOMO and LUMO) and their energy gap ( $\Delta E_{\text{gap}}$ ) of **6Ec** were calculated using the DFT/B3LYP/6-31G method.

$\Delta G_{\text{bindCoulomb}}$  made an important contribution, but its energy was 10 kcal higher than the standard.  $\Delta G_{\text{bindCovalent}}$  and  $\Delta G_{\text{bindHbond}}$  made moderate contributions. In contrast,  $\Delta G_{\text{bindSolvGB}}$  showed unfavorable energy contributions and thus opposed binding. Furthermore, the greater number of lipophilic contacts in the MD simulation and docking of **6Ec** is corroborated by the higher value of  $\Delta G_{\text{bindlip}}$ . Additionally docking and MD studies revealed that, **6Ec** and the **bio-acetoxime** (standard) showed comparable H-bonds with proteins, as evidenced by their close  $\Delta G_{\text{bindHbond}}$  values.

**3.5.7. Correlation of DFT study with docking and MD simulation of 6Ec.** Compound **6Ec** demonstrated the highest cytotoxicity, a greater docking score, and significant protein–ligand stability in the MD simulation study. Furthermore, DFT research was conducted to determine how the molecular and electrical characteristics of **6Ec** influence biological activity.

The lowest energy of optimization in the ground suggests the most stable conformation of **6Ec** (obtained using the B3LYP/6-31G(d) level of theory). It had a higher dipole moment implies a greater potential to undergo polar interaction with the target protein, which was justified *via* pi-cation and H-bond interaction in the docking (Fig. 10 and Table 3).




Fig. 12 Molecular electrostatic potential plots of **6Ec** calculated using the DFT/B3LYP/6-31G(d) method.

In order to understand molecular properties of a neutral system, we calculated the highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO). The energy gap between EHOMO and ELUMO was found to be 0.12559 eV, which was less than 0.2 eV, indicating significant chemical reactivity and less kinetic stability of the molecules (Fig. 11). These findings were also supported by higher softness and lower hardness values. Together, these might reflect that **6Ec** had a higher affinity for the target protein. Furthermore, lower values of ionization potential and chemical potential showed that the compound had a considerable inclination to accommodate the ionic state as well as greater reactivity towards the target (Table 4), which has verified the finding of approximately six types of total interaction in the MD investigation. Furthermore, increased reactivity of **6Ec** was observed in docking studies *via* multiple types of lipophilic, pi-cation, and H-bond interactions. Furthermore, lower values of electronegativity, electron affinity, and electrophilicity index may suggest that **6Ec** had a less electron-loving nature, which could be due to the presence of an electron-donating group-containing ring such as *p*-methoxyphenyl, as well as basic hydrazone linkage and a triazole ring. Furthermore, HOMO images revealed a greater electron density on the indole to phenylhydrazone area. In contrast, the indole ring had a higher concentration of LUMO than the phenylhydrazone ring, which could be attributed to the presence of an electron-withdrawing carbonyl group. It resulted in a higher electron deficit in LUMO, which may be cause of one lipophilic contact with Val70 during the docking experiment.

Table 4 Global and local reactivity descriptors of compound **6Ec**

$E_{\text{HOMO}}^a$ (eV)	$E_{\text{LUMO}}^b$ (eV)	$\Delta E_{\text{gap}}^c$ (eV)	$I^d$ (eV)	$A^e$ (eV)	$\mu^f$ (eV)	$\chi^g$ (eV)	$\eta^h$ (eV)	$S^i$ (eV)	$\omega^j$ (eV)
-0.19345	-0.06786	0.12559	0.19345	0.06786	-0.130655	0.130655	0.062795	7.962417	0.135975

<sup>a</sup> Energy of HOMO. <sup>b</sup> Energy of LUMO. <sup>c</sup> Energy gap between HOMO & LUMO. <sup>d</sup> Ionization potential. <sup>e</sup> Electron affinity. <sup>f</sup> Chemical potential. <sup>g</sup> Electronegativity. <sup>h</sup> Hardness. <sup>i</sup> Softness. <sup>j</sup> Electrophilicity index.



Table 5 *In silico* ADME data for the compounds **6Eb**, **6Ec** and bio-acetoxime

Compound code	Binding affinity	MW	$F_{sp^3}$	RB	HBA	HBD	tPSA	log $P$	Lipinski	ESOL log $S$	ESOL class	log KP	$F$
<b>6Eb</b>	−8.8	421.48	0.15	7	5	2	142.75	1.98	0	−3.75	Soluble	−7.36	0.55
<b>6Ec</b>	−10.1	438.48	0.12	7	5	1	84.64	2.96	0	−5.08	Moderately soluble	−6.19	0.55
<b>Bio-acetoxime</b>	−7.7	73.09	0.67	0	2	1	32.59	1.22	0	−0.37	Very soluble	−6.66	0.55

Also, the molecular electrostatic potential (MEP) map tells about reactivity regions in an organic molecule depending upon the electron density of each atom, which is the most probable region for electrophilic attack. Here, different colors represent different values of electrostatic potential, molecular size, and shape. Potential increases in order from red < orange < yellow < green < blue.<sup>39–41</sup> High electron density is manifested by the red zone towards the triazole ring, hydrazone linkage, and oxygen of indole in the MEP map (Fig. 12). On the other hand, a phenylhydrazone ring oriented towards yellow color indicates a slightly electron-rich region, which may be due to the electron-releasing property of the hydrazone ring. These observations also supported multiple lipophilic and polar interactions of phenylhydrazone with Ala83, Val110, Leu132, Leu188, Cys199, and Asp200 in the docking and MD study. Taken together, the promising electrical and molecular features of **6Ec** warrant further biological investigation.

**3.5.8. *In silico* ADME determination.** Synthesized compounds **6Eb** and **6Ec** demonstrated significant cytotoxicity and kinase inhibition as well as greater stability in the *in silico* work. As a result, those two compounds were examined for an *in silico* ADME investigation. The parameters molecular weight (MW), lipophilicity (log  $P$ ), topological polar surface area (tPSA), and Lipinski's rule of five (Ro5) were computed using the Swiss-ADME web server.

*In silico* results summarized in (Table 5) reveal that compound **6Ec** had a greater drug-likeness property over **6Eb** and standard among the studies. **6Ec** exhibited a tPSA value (84.64 Å<sup>2</sup>) within the range of ≤140, which is ideal for improved oral absorption and intestinal permeability. Both compounds showed H-bonds within the range, indicating that aqueous solubility and binding affinity were optimized without compromising solubility. Both compounds **6Eb** and **6Ec** had excellent log  $P$  values (2.96 and 1.98), indicating sufficient lipophilicity to permeate cellular membranes without CNS damage. Further, **6Eb** and **6Ec** had optimum number of rotatable bonds, which may led to greater rigidity, higher binding affinity, and lower conformational changes during target engagement. Besides,  $F_{sp^3}$  indicates a saturation of sp<sup>3</sup> hybridized carbons. A greater score of  $F_{sp^3}$  indicates a drug's similarity with known medicines, which often contain a larger proportion of saturated carbon atoms. Also, drug–drug interactions, metabolic interactions, and toxicity typically decrease with increasing  $F_{sp^3}$  values. While, **6Ec** exhibited a lower  $F_{sp^3}$  value compared to **bio-acetoxime** (standard), suggesting a more rigid interaction with the target. The finding collectively reflects that **6Ec** had a better ADME profile than **6Eb** and **bio-acetoxime** (standard). Moreover, it demonstrated a balanced set of properties favouring optimal absorption, distribution, and target

binding. Additionally, it met the necessary tPSA, lipophilicity,  $F_{sp^3}$ , and binding affinity. These characteristics collectively suggest that **6Ec** could be a promising candidate with better pharmacokinetics and smaller metabolic liabilities.

## 4. Conclusions

The current work examines the cytotoxic effects of newly synthesized hydrazone-2-oxindole analogues against several cancer cell lines. The compound **6Cb** exhibited cytotoxicity against the LN229 cell line (CC<sub>50</sub>: 12.22 μM). The other two compounds, **6Eb** and **6Ec**, demonstrated the maximum cytotoxicity against the MOLT4 cells (2.7 μM and 0.9 μM) followed by Capan-1 cell line (CC<sub>50</sub>: 9.40 μM and 8.25 μM, respectively). These compounds **6Eb** and **6Ec** were non-toxic to normal cells (HEK 293 IC<sub>50</sub> 46 μM and 144 μM respectively). Furthermore, the compounds **6Eb** and **6Ec** strongly inhibited GSK-3β, indicating an anticancer mechanism. In western blot, **6Eb** enhanced the β-catenin fraction and decreased NF-κB and STAT3 expression, confirming its anticancer mechanism. Also, docking and MD tests corroborated cytotoxicity, kinase inhibition, and western blotting results, demonstrating that compound **6Eb** inhibited GSK-3β activity. Moreover, DFT analysis revealed electron-rich and deficient regions on molecules, which were used to compare non-polar and polar interactions with kinase in docking and MD studies. Likewise, *in silico* ADMET discovered the drug-like properties of the proposed molecule, demonstrating its novelty as a potential lead. However, the study findings indicate that additional *in vivo* and biochemical studies are required to evaluate the efficacy and safety of **6Eb** and **6Ec**, strengthening their potential as therapeutic agents.

## Abbreviations

<i>p</i> -SMAD3	Mothers against decapentaplegic homolog 3
c-Myc	Cellular Myc
DTT	Dithiothreitol
PDBQT	Protein data bank, partial charge, and atom type
OPLS	Optimised potential for liquid simulations
TIP3P	Transferable intermolecular potential with three point
MM-GBSA	Molecular mechanics/generalised born surface area
NF-κB	Nuclear factor kappa-light enhancer of activated B cells
PTEN	Phosphatase and tensin homolog



STAT3	Signal transducer and activation of transcription 3
RMSD	Root mean square deviation
RMSF	Root mean square fluctuations
$\Delta G_{\text{bind}}$	Binding free energy
$\Delta G_{\text{bindLipo}}$	Lipophilic contribution to the overall binding free energy of a ligand–protein complex
$\Delta G_{\text{bindvdW}}$	van der Waals force contribution to the overall binding free energy of a ligand–protein complex
$\Delta G_{\text{bindCoulomb}}$	Change in Gibbs free energy of binding that is specifically attributed to electrostatic interactions (coulomb interactions) between a ligand and a protein or receptor
$\Delta G_{\text{bindHbond}}$	Binding free energy of hydrogen bonds
$\Delta G_{\text{bindSolvGB}}$	Binding free energy of solvation
$\Delta G_{\text{bindCovalent}}$	Binding free energy of covalent bond
MEP	Molecular electrostatic potential
ADME	Absorption, distribution, metabolism and elimination

## Data availability

The data are included within the article and in ESI.†

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

Thanks to Saumya K. Patel and Nandan Dixit from the Department of Botany, bioinformatics and climate change impacts management, School of Science, Gujarat University, Ahmedabad, Gujarat, India, for providing the MD simulation study.

## References

- N. Embi, D. B. Rylatt and P. Cohen, *Eur. J. Biochem.*, 1980, **107**, 519–527.
- A. J. Harwood, *Cell*, 2001, **105**, 821–824.
- H. Yao, P. Shaw, C. Wrong and D. C. Wan, *J. Chem. Neuroanat.*, 2002, **23**, 291–297.
- J. R. Woodgett, *EMBO J.*, 1990, **9**, 2431–2438.
- H. Eldar-Finkelman, *Trends Mol. Med.*, 2002, **8**, 126–132.
- B. W. Doble and J. R. Woodgett, *J. Cell Sci.*, 2003, **116**, 1175–1186.
- R. S. Jope, C. J. Yuskaitis and E. Beurel, *Neurochem. Res.*, 2007, **32**, 577–595.
- S. Frame and P. Cohen, *Biochem. J.*, 2001, **359**, 1–16.
- L. Kim and A. R. Kimmel, *Curr. Opin. Genet. Dev.*, 2000, **10**, 508–514.
- A. S. Wagman and J. M. Nuss, *Curr. Pharm. Des.*, 2001, **7**, 417–450.
- P. Cohen, *Eur. J. Biochem.*, 2001, **268**, 5001–5010.
- C. Sasaki, T. Hayashi, W. R. Zhang, H. Warita, Y. Manabe, K. Sakai and K. Abe, *Neurol. Res.*, 2001, **23**, 588–592.
- A. Castro and A. Martinez, *Expert Opin. Ther. Pat.*, 2000, **10**, 1519–1527.
- J. A. Bertrand, S. Thieffine, A. Vulpetti, C. Cristiani, B. Valsasina, S. Knapp, H. M. Kalisz and M. Flocco, *J. Mol. Biol.*, 2003, **333**, 393–407.
- I. Hers, J. M. Tavares and R. M. Denton, *FEBS Lett.*, 1999, **460**, 433–436.
- H.-C. Zhang, K. B. White, H. Ye, D. F. McComsey, C. K. Derian, M. F. Addo, P. Andrade-Gordon, A. J. Eckardt, B. R. Conway, L. Westover, J. Z. Xu, R. Look, K. T. Demarest, S. Emanuel and B. E. Maryanoff, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 3049–3053.
- E. erHaar, J. T. Coll, D. A. Austen, H. M. Hsiao, L. Swenson and J. Jain, *Nat. Struct. Biol.*, 2001, **8**, 593–596.
- R. Dajani, E. Fraser, S. M. Roe, N. Young, V. Good, T. C. Dale and L. H. Pearl, *Cell*, 2001, **105**, 721–732.
- Q. Ye, Y. Shen, Y. Zhou, D. Lv, J. Gao, J. Li and Y. Hu, *Eur. J. Med. Chem.*, 2013, **68**, 361–371.
- L. Gong, D. Hirschfeld, Y. C. Tan, *et al.*, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 1693–1696.
- A. M. Aronov, T. Qing, G. Martinez-Botella, *et al.*, *J. Med. Chem.*, 2009, **52**, 6362–6368.
- H. Zou, L. Zhou, Y. Li, *et al.*, *J. Med. Chem.*, 2010, **53**, 994–1003.
- L. Meijer, A. L. Skaltsounis, P. Magiatis, *et al.*, *Chem. Biol.*, 2003, **10**, 1255–1266.
- P. Polychronopoulos, P. Magiatis, A. L. Skaltsounis, *et al.*, *J. Med. Chem.*, 2004, **47**, 935–946.
- J. A. Bertrand, S. Thieffine, A. Vulpetti, *et al.*, *J. Mol. Biol.*, 2003, **333**, 393–407.
- J. Witherington, V. Bordas, D. Haigh, *et al.*, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 1581–1584.
- M. Saitoh, J. Kunitomo, E. Kimura, *et al.*, *Bioorg. Med. Chem.*, 2009, **17**, 2017–2029.
- M. L. Selenica, H. S. Jensen, A. K. Larsen, *et al.*, *Br. J. Pharmacol.*, 2007, **152**, 959–979.
- A. Martinez, M. Alonso, A. Castro, C. Pérez and F. J. Moreno, *J. Med. Chem.*, 2002, **45**, 1292–1299.
- T. Kramer, B. Schmidt and F. Lo Monte, *Int. J. Alzheimers Dis.*, 2012, **2012**, 381029.
- P. Polychronopoulos, P. Magiatis, A. L. Skaltsounis, V. Myrianthopoulos, E. Mikros, A. Tarricone, A. Musacchio, S. M. Roe, L. Pearl, M. Leost, P. Greengard and L. Meijer, *J. Med. Chem.*, 2004, **47**, 935–946.
- K. Vougiannopoulou, Y. Ferandin, K. Bettayeb, *et al.*, *J. Med. Chem.*, 2008, **51**, 6421–6431.
- A. Das, G. Greco, S. Kumar, E. Catanzaro, R. Morigi, A. Locatelli, D. Schols, H. Alici, H. Tahtaci, F. Ravindran, C. Fimognari and S. S. Karki, *Comput. Biol. Chem.*, 2023, **97**, 107641.
- K. Aman, K. Lal, M. Murtaza, S. Jaglan, Y. Rohila, P. Singh, M. B. Singh and K. Kumari, *J. Biomol. Struct. Dyn.*, 2024, **42**, 9919–9938.
- T. V. de Walle, A. Theppawong, C. Grootaert, S. D. Jonghe, L. Persoons, D. Daelemans, K. V. Hecke, J. V. Camp and M. D'hooghe, *Monatsh. Chem.*, 2019, **150**, 2045–2051.
- O. Trott and A. J. Olson, *J. Comput. Chem.*, 2010, **31**, 455–461.



## Paper

- 37 D. Yevale, N. Teraiya, T. Lalwani, M. Dalasaniya, K. Kapadiya, R. K. Ameta, C. B. Sangani and Y. T. Duan, *Bioorg. Chem.*, 2024, **147**, 107323.
- 38 S. Rajamanikandan, J. Jeyakanthan and P. Srinivasan, *Appl. Biochem. Biotechnol.*, 2017, **181**, 192–218.
- 39 K. K. Bharadwaj, T. Sarkar, A. Ghosh, D. Baishya, B. Rabha, M. Panda, B. R. Nelson, A. John, H. I. Sheikh, B. P. Dash, H. A. Edinur and S. Pati, *ChemRxiv*, 2021, **193**, 3371–3394.
- 40 L. Piao, Z. Chen, Q. Li, R. Liu, W. Song, R. Kong and S. Chang, *Int. J. Mol. Sci.*, 2019, **20**, 224.
- 41 M. Kawad, S. Sangani, J. K. Parmar, R. C. Dabhi, P. S. Arya, N. Teraiya, S. Ahmed and R. K. Ameta, *Polyhedron*, 2024, **264**, 117242.
- 42 A. Diana, O. Michielin and V. Zoete, *Sci. Rep.*, 2017, **7**, 42717.
- 43 D. F. Veber, S. R. Johnson, H. Y. Cheng, B. R. Smith, K. W. Ward and K. D. Kopple, *J. Med. Chem.*, 2002, **45**, 2615–2623.

